

**PCR-/NAT *Mycoplasma pneumoniae*
 (RV 541) November 2022**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
2225411	∅	62	<i>Escherichia coli</i> K12
2225412	+++	61	<i>Mycoplasma pneumoniae</i> (~ 5x10 ⁵ genome copies/mL)
2225413	++	61	<i>Mycoplasma pneumoniae</i> (~ 5x10 ⁴ genome copies/mL)
2225414	+	61	<i>Mycoplasma pneumoniae</i> (~ 5x10 ³ genome copies/mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n = 144</i>	<i>Probennummer (Sample no.)</i>					<i>Inhibition</i>			
	<i>2225411</i>	<i>2225412</i>	<i>2225413</i>	<i>2225414</i>		<i>2225411</i>	<i>2225412</i>	<i>2225413</i>	<i>2225414</i>
Befund <i>Result</i>									
Positiv	3	144	144	135	n.d.	0	0	0	0
Negativ	141	0	0	9	nein <i>no</i>	144	144	144	144
Fraglich <i>Questionable</i>	0	0	0	0	ja <i>yes</i>	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number)	NAT richtig positiv <i>True positive results</i>						NAT richtig negativ	
	2225412		2225413		2225414		2225411	
	<i>Absolut</i> <i>Absolute</i>	<i>%</i>	<i>Absolut</i> <i>Absolute</i>	<i>%</i>	<i>Absolut</i> <i>Absolute</i>	<i>%</i>	<i>Absolut</i> <i>Absolute</i>	<i>%</i>
AID CAP bacteria (n= 7)	7	100	7	100	7	100	7	100
ARGENE Chla/Myco pneumo (n= 7)	7	100	7	100	7	100	7	100
Amplex eazyplex PneumoBug exp. (n= 2)	2	100	2	100	1	50	2	100
AmpliGnost M. pneumoniae (n= 6)	6	100	6	100	6	100	6	100
AmpliSens M.pn./C.pn. FRT Kit (n= 1)	1	100	1	100	0	0	1	100
FILMARRAY Resp. Panel 2.1 plus (n= 2)	2	100	2	100	2	100	2	100

BioGx auf BD Max (n= 9)	9	100	9	100	9	100	9	100
Biologio ReadyMax b-CAP Assay (n= 2)	2	100	2	100	1	50	2	100
FTD Atypical CAP (n= 2)	2	100	2	100	2	100	2	100
FTD Respiratory Pathogens 21 (n= 1)	1	100	1	100	1	100	1	100
GeneProof M. pneumoniae (n= 11)	11	100	11	100	10	91	11	100
Luminex MagPix Resp. Pathogen (n= 1)	1	100	1	100	0	0	1	100
Mikrogen Diagenode M.pn./C.pn. (n= 1)	1	100	1	100	1	100	1	100
ampliCube Resp. panel 1 (n= 9)	9	100	9	100	9	100	9	100
Alethia Mycoplasma direct (n= 2)	2	100	2	100	2	100	2	100
Sacace M.pn./C.pn. Real-TM (n= 2)	2	100	2	100	2	100	2	100
Sartorius Microsart ATMP Mycopl. (n= 2)	2	100	2	100	2	100	0	0
Seegene Allplex Resp. Panel 4 (n= 15)	15	100	15	100	14	93	15	100
LightMix M. pneumoniae (n= 12)	12	100	12	100	10	83	12	100
RIDAGENE M. pneumoniae (n= 2)	2	100	2	100	2	100	2	100
In house PCR assay (n= 35)	35	100	35	100	34	97	34	97
Other commercial tests (n= 13)	13	100	13	100	13	100	13	100

Comments:

1. Unter "Andere kommerzielle Testsysteme" sind folgende Testsysteme aufgeführt: r-Biopharm RIDAGENE CAP Bac (4x), Seegene Allplex PneumoBacter assay (2x), PathoFinder RespiFinder 2Smart (1x), AusDiagnostics Atypical Pneumonia 8-well (1x), AusDiagnostics Pneumonia 16-well (1x), Ingenetix BactoReal M. pneumoniae (1x), MIKROGEN ampliCube Respiratory Bacterial Panel 1.1 (1x), QIAGEN QIAstat-Dx Respiratory Sars CoV-2 panel (1x), TIB Molbiol LightMix modular Mycoplasma (1x) und CerTest VIASURE (1x).